Robert Jakubowski
Internal Medicine · San Antonio, TXNPI 1780654475
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,131 and has fallen 97.6% since, to $27 in 2024.
Across 214 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$691
- Amgen$677
- Lilly USA, LLC$403
- Novo Nordisk$292
- Bayer$220
- Pfizer$214
- plus $2K from 29 others
What the payments were for
- Consulting fees$1764%
- Speaking & faculty fees$271%
- Food & beverage$3,78994%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $691 |
| Amgen | 25 | $677 |
| Lilly USA, LLC | 27 | $403 |
| Novo Nordisk | 16 | $292 |
| Bayer | 12 | $220 |
| Pfizer | 9 | $214 |
| Medtronic(2 entities) | 3 | $199 |
| Avanir Pharmaceuticals, Inc. | 9 | $148 |
| Teva Pharmaceuticals USA, Inc. | 8 | $131 |
| Novartis | 8 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $95 |
| GSK | 5 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| AstraZeneca | 3 | $59 |
| Scilex Pharmaceuticals Inc. | 4 | $59 |
| Boehringer Ingelheim | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $41 |
| Abbott | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| Pacira Therapeutics, Inc. | 2 | $35 |
| Tersera Therapeutics LLC | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| BD | 1 | $27 |
| Merck | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Intuity Medical Inc | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Vistapharm, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,011 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $15,531 |
| MounjaroTirzepatide | 13 | $14,103 |
| EliquisApixaban | 19 | $13,833 |
| TrulicityDulaglutide | 11 | $8,568 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $1,150 |
| Gabapentin | 35 | $470 |
| Levocetirizine Dihydrochloride | 11 | $429 |
| Pantoprazole Sodium | 28 | $382 |
| Levothyroxine Sodium | 44 | $376 |
| Lisinopril | 19 | $307 |
| Omeprazole | 20 | $276 |
| Atorvastatin Calcium | 25 | $262 |
| Montelukast Sodium | 23 | $251 |
| Duloxetine Hcl | 15 | $247 |
| Fluticasone Propionate | 12 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $403 | $22,67124 claims |
| Boehringer IngelheimJardiance | $44 | $15,53119 claims |
| PfizerEliquis | $214 | $13,83319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in San Antonio
- Manuel RodriguezSan Antonio$263K
- Matthew CatesSan Antonio$248K
- Fabian Rodas OchoaSan Antonio$68K
- Darius BuzenasSan Antonio$49K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.